OldenbuettelC., WolfE., RitterA.Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results.Antivir Ther2016; doi: 10.3851/IMP3082.
2.
RojasJ., BlancoJ.L., MarcosM.A.Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression.J Antimicrob Chemother2016; 71: 1975–1981.
3.
KatlamaC., SouliéC., CabyF.Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia.J Antimicrob Chemother2016; 71: 2646–2650.
4.
GubavuC., PrazuckT., NiangM.Dolutegravir-based monotherapy or dual therapy maintains a high proporition of viral suppression even in highly-experience HIV-1-infected patients.J Antimicrob Chemother2016; 71: 1046–1050.
5.
RojasJ., BlancoJ.L., LoncaM.Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression: a 24-week pilot study.15th European AIDS Conference. 21–24 October 2015, Barcelona, Spain. Abstract LBPS4/2.
6.
CahnP., RolonM.J., FigueroaM.I., GunA., PattersonP., SuedO.Dolutegravir-lamivudine as initial therapy in HIV-infected, ARV naive patients: 48 week results of the PADDLE trial.21st International AIDS Conference. 18–22 July 2016, Durban, South Africa. Abstract FRAB004LB.
7.
FigueroaM.I., SuedO., PattersonP., GunA., RolonM.J., CahnP.Dolutegravir-lamivudine as initial therapy in HIV-infected, ARV naive patients: first results of the PADDLE trial.15th European AIDS Conference. 21–24 October 2015, Barcelona, Spain. Abstract LBPS4/1.
8.
GünthardH.F., SaagM.S., BensonC.A.Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel.JAMA2016; 316: 191–210.
9.
Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.Department of Health and Human Services. (Accessed 15 September 2016.) Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.